Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safusidenib - AnHeart Therapeutics

Next Previous
Drug Profile

Safusidenib - AnHeart Therapeutics

Alternative Names: AB-218; DS-1001; DS-1001b

Latest Information Update: 25 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company; National Cancer Center (Tokyo)
  • Developer AnHeart Therapeutics; Daiichi Sankyo Company; National Cancer Center (Tokyo)
  • Class Alkenes; Antineoplastics; Carboxylic acids; Chlorobenzenes; Fluorinated hydrocarbons; Indoles; Isoxazoles; Ketones; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioma
  • No development reported Acute myeloid leukaemia; Chondrosarcoma; Solid tumours
  • Discontinued Cholangiocarcinoma

Most Recent Events

  • 21 Sep 2026 University of Zurich in collaboration with Nuvation Bio plans a phase II SAFU-G3 trial for Oligodendroglioma and Astrocytoma (First line therapy) in Switzerland (PO) (NCT07832123)
  • 20 Aug 2026 Safusidenib receives Fast Track designation for Glioma [PO] (Recurrent, Second-line therapy or greater, Late-stage disease) in USA
  • 20 Jul 2026 Efficacy and adverse events data from the phase II trial in Glioma released by Nuvation Bio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top